In BLISS-76, 43.2% (118/273) of the high-dose belimumab group compared with 33.8% (93/275) of the placebo group achieved the primary endpoint at week 52. 7 This difference, although modest in ...

Infusion reaction rates were somewhat higher in groups treated with belimumab. In the BLISS-76 study, patients were divided into three different groups (as in BLISS-52): belimumab 1 mg/kg ...

The FDA approval comes on the back of the BLISS-LN trial results, which showed that 43% of patients on Benlysta hit the target of a significant improvement in kidney function, compared with 32% of ...

Belimumab combined with SOC was successful for inducing remission among patients with SLE, including those with LN.